Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Steve Millerman, General Manager, Fingerpaint Multicultural

Advertisement

Articles by Steve Millerman, General Manager, Fingerpaint Multicultural

The opportunity to evolve the oncology model is ready and waiting

ByPaul Hagopian, Chief Growth Officer, Fingerpaint Group,Steve Millerman, General Manager, Fingerpaint Multicultural
June 1st 2023

Brand Insights - Thought Leadership | Paid Program

Advertisement

Latest Updated Articles

  • The opportunity to evolve the oncology model is ready and waiting
    The opportunity to evolve the oncology model is ready and waiting

    June 1st 2023



Advertisement
Advertisement

Trending on PharmExec

1

Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink

2

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

3

Additive Manufacturing's Application in Pharma and Biotech

4

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A

5

How is Boehringer Ingelheim's Deliberate GLP-1 Strategy Different From Competitors?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us